Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 211

1.

TMIGD1 acts as a tumor suppressor through regulation of p21Cip1/p27Kip1 in renal cancer.

Meyer RD, Zou X, Ali M, Ersoy E, Bondzie PA, Lavaei M, Alexandrov I, Henderson J, Rahimi N.

Oncotarget. 2017 Dec 26;9(11):9672-9684. doi: 10.18632/oncotarget.23822. eCollection 2018 Feb 9.

2.

MINAR1 is a Notch2-binding protein that inhibits angiogenesis and breast cancer growth.

Ho RX, Meyer RD, Chandler KB, Ersoy E, Park M, Bondzie PA, Rahimi N, Xu H, Costello CE, Rahimi N.

J Mol Cell Biol. 2018 Jun 1;10(3):195-204. doi: 10.1093/jmcb/mjy002.

PMID:
29329397
3.

HIV prevention trial design in an era of effective pre-exposure prophylaxis.

Cutrell A, Donnell D, Dunn DT, Glidden DV, Grobler A, Hanscom B, Stancil BS, Meyer RD, Wang R, Cuffe RL.

HIV Clin Trials. 2017 Nov-Dec;18(5-6):177-188. doi: 10.1080/15284336.2017.1379676. Epub 2017 Oct 17. Review.

4.

Targeting tumor multicellular aggregation through IGPR-1 inhibits colon cancer growth and improves chemotherapy.

Woolf N, Pearson BE, Bondzie PA, Meyer RD, Lavaei M, Belkina AC, Chitalia V, Rahimi N.

Oncogenesis. 2017 Sep 18;6(9):e378. doi: 10.1038/oncsis.2017.77.

5.

Site-Specific N-Glycosylation of Endothelial Cell Receptor Tyrosine Kinase VEGFR-2.

Chandler KB, Leon DR, Meyer RD, Rahimi N, Costello CE.

J Proteome Res. 2017 Feb 3;16(2):677-688. doi: 10.1021/acs.jproteome.6b00738. Epub 2016 Dec 29.

6.

IGPR-1 Is Required for Endothelial Cell-Cell Adhesion and Barrier Function.

Wang YHW, Meyer RD, Bondzie PA, Jiang Y, Rahimi I, Rezazadeh K, Mehta M, Laver NMV, Costello CE, Rahimi N.

J Mol Biol. 2016 Dec 4;428(24 Pt B):5019-5033. doi: 10.1016/j.jmb.2016.11.003. Epub 2016 Nov 9.

7.

Nonunion of first rib fracture in a softball player: case report of a rare cause of thoracic outlet syndrome.

Young BL, Watson SL, Meyer RD, Ponce BA.

J Shoulder Elbow Surg. 2016 Nov;25(11):e353-e357. doi: 10.1016/j.jse.2016.07.025. No abstract available.

PMID:
27742249
8.

c-Cbl mediates the degradation of tumorigenic nuclear β-catenin contributing to the heterogeneity in Wnt activity in colorectal tumors.

Shashar M, Siwak J, Tapan U, Lee SY, Meyer RD, Parrack P, Tan J, Khatami F, Francis J, Zhao Q, Hartshorn K, Kolachalama VB, Rahimi N, Chitalia V.

Oncotarget. 2016 Nov 1;7(44):71136-71150. doi: 10.18632/oncotarget.12107.

9.

RNF121 Inhibits Angiogenic Growth Factor Signaling by Restricting Cell Surface Expression of VEGFR-2.

Maghsoudlou A, Meyer RD, Rezazadeh K, Arafa E, Pudney J, Hartsough E, Rahimi N.

Traffic. 2016 Mar;17(3):289-300. doi: 10.1111/tra.12353. Epub 2015 Dec 21.

10.

TMIGD1 is a novel adhesion molecule that protects epithelial cells from oxidative cell injury.

Arafa E, Bondzie PA, Rezazadeh K, Meyer RD, Hartsough E, Henderson JM, Schwartz JH, Chitalia V, Rahimi N.

Am J Pathol. 2015 Oct;185(10):2757-67. doi: 10.1016/j.ajpath.2015.06.006. Epub 2015 Sep 2.

11.

Clinical response and mortality in tigecycline complicated intra-abdominal infection and complicated skin and soft-tissue infection trials.

Bassetti M, McGovern PC, Wenisch C, Meyer RD, Yan JL, Wible M, Rottinghaus ST, Quintana A.

Int J Antimicrob Agents. 2015 Sep;46(3):346-50. doi: 10.1016/j.ijantimicag.2015.05.012. Epub 2015 Jun 25.

12.

The novel function of JADE1S in cytokinesis of epithelial cells.

Siriwardana NS, Meyer RD, Panchenko MV.

Cell Cycle. 2015;14(17):2821-34. doi: 10.1080/15384101.2015.1068476. Epub 2015 Jul 7.

13.

Hypoxia-induced expression of phosducin-like 3 regulates expression of VEGFR-2 and promotes angiogenesis.

Srinivasan S, Chitalia V, Meyer RD, Hartsough E, Mehta M, Harrold I, Anderson N, Feng H, Smith LE, Jiang Y, Costello CE, Rahimi N.

Angiogenesis. 2015 Oct;18(4):449-62. doi: 10.1007/s10456-015-9468-3. Epub 2015 Jun 10.

14.

First prospective comparison of genotypic vs phenotypic tropism assays in predicting virologic responses to Maraviroc (MVC) in a phase 3 study: MODERN.

Heera J, Valluri S, Craig C, Fang A, Thomas N, Meyer RD, Demarest J.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19519. doi: 10.7448/IAS.17.4.19519. eCollection 2014.

15.

Lysine methylation promotes VEGFR-2 activation and angiogenesis.

Hartsough EJ, Meyer RD, Chitalia V, Jiang Y, Marquez VE, Zhdanova IV, Weinberg J, Costello CE, Rahimi N.

Sci Signal. 2013 Dec 3;6(304):ra104. doi: 10.1126/scisignal.2004289.

16.

Identification of PDCL3 as a novel chaperone protein involved in the generation of functional VEGF receptor 2.

Srinivasan S, Meyer RD, Lugo R, Rahimi N.

J Biol Chem. 2013 Aug 9;288(32):23171-81. doi: 10.1074/jbc.M113.473173. Epub 2013 Jun 21.

17.

All-cause mortality imbalance in the tigecycline phase 3 and 4 clinical trials.

McGovern PC, Wible M, El-Tahtawy A, Biswas P, Meyer RD.

Int J Antimicrob Agents. 2013 May;41(5):463-7. doi: 10.1016/j.ijantimicag.2013.01.020. Epub 2013 Mar 26.

18.

Identification of IGPR-1 as a novel adhesion molecule involved in angiogenesis.

Rahimi N, Rezazadeh K, Mahoney JE, Hartsough E, Meyer RD.

Mol Biol Cell. 2012 May;23(9):1646-56. doi: 10.1091/mbc.E11-11-0934. Epub 2012 Mar 14.

19.

PEST motif serine and tyrosine phosphorylation controls vascular endothelial growth factor receptor 2 stability and downregulation.

Meyer RD, Srinivasan S, Singh AJ, Mahoney JE, Gharahassanlou KR, Rahimi N.

Mol Cell Biol. 2011 May;31(10):2010-25. doi: 10.1128/MCB.01006-10. Epub 2011 Mar 14.

20.

c-Cbl inhibits angiogenesis and tumor growth by suppressing activation of PLCγ1.

Meyer RD, Husain D, Rahimi N.

Oncogene. 2011 May 12;30(19):2198-206. doi: 10.1038/onc.2010.597. Epub 2011 Jan 17.

Supplemental Content

Loading ...
Support Center